Abstract
Original language | English |
---|---|
Pages (from-to) | 12-39 |
Number of pages | 28 |
Journal | International journal of gynecological cancer |
Volume | 31 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 2021 |
Keywords
- pathology
- radiation
- surgery
- uterine cancer
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: International journal of gynecological cancer, Vol. 31, No. 1, 01.01.2021, p. 12-39.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
AU - Concin, Nicole
AU - Matias-Guiu, Xavier
AU - Vergote, Ignace
AU - Cibula, David
AU - Mirza, Mansoor Raza
AU - Marnitz, Simone
AU - Ledermann, Jonathan
AU - Bosse, Tjalling
AU - Chargari, Cyrus
AU - Fagotti, Anna
AU - Fotopoulou, Christina
AU - Gonzalez Martin, Antonio
AU - Lax, Sigurd
AU - Lorusso, Domenica
AU - Marth, Christian
AU - Morice, Philippe
AU - Nout, Remi A.
AU - O'Donnell, Dearbhaile
AU - Querleu, Denis
AU - Raspollini, Maria Rosaria
AU - Sehouli, Jalid
AU - Sturdza, Alina
AU - Taylor, Alexandra
AU - Westermann, Anneke
AU - Wimberger, Pauline
AU - Colombo, Nicoletta
AU - Planchamp, François
AU - Creutzberg, Carien L.
N1 - Funding Information: Competing interests NCon: advisory boards for Seattle Genetics, AstraZeneca and Mersana, education fees from Medscape Oncology, and grants for travelling from Roche, Genmab and Amgen. IV: advisory boards for Amgen, AstraZeneca, Clovis Oncology, Carrick Therapeutics, Debiopharm International, F Hoffmann-La Roche, Genmab, GSK, Immunogen, Millenium Pharmaceuticals, MSD Belgium, Octimet Oncology, Oncoinvent, Pharmamar-Doctaforum Servicios, Roche, Sotio, Tesaro, Deciphera Pharmaceuticals and Verastem Oncology (fees for consulting to his university), contracted research (KU Leuven) for Oncoinvent AS and Genmab, corporate sponsored research for Amgen and Roche, and grants for travelling from Amgen, MSD/Merck, Roche, AstraZeneca and Tesaro. DC: advisory boards for AstraZeneca, Roche, Sotio and Novocure. MRM: personal financial interests for AstraZeneca, Biocard, Clovis Oncology, Geneos, Genmab, Karyopharm Therapeutics, Merck, Mersana, MSD, Oncology Venture, Pfizer, Roche, SeatleGenetics, SeraPrognostics, Sotio, Tesaro-GSK, ZaiLab; leadership role for Karyopharm Therapeutics, Sera Prognostics; institutional financial interests (study grants) for AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer, Tesaro-GSK, Ultimovacs. JL: advisory boards for AstraZeneca, Pfizer, GSK, Eisai, MSD/ Merck, Artios Pharma, Regeneron, Amgen and Clovis Oncology, and grants for travelling from Clovis Oncology. CC: advisory boards for MSD, Takeda and GSK, conducting research for TherAguiX and Roche, and grants for travelling from Takeda. AF: advisory boards for GSK and Johnson & Johnson SpA, and grants for travelling from Pharmmar and MSD Italia. CF: advisory boards for AstraZeneca, Clovis, Ethicon, Roche, MSD, GSK and Tesaro, and grants for travelling from Sequana. AGM: speakers’ bureau activities for AstraZeneca, Pharmamar, Roche and GSK, advisory boards for Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, Immunogen, Merck Sharp & Dohme, Novartis, Oncoinvent, Pfizer/Merck, Pharmamar, Roche and Sotio, and grants for travelling from AstraZeneca, Pharmamar Roche and Tesaro. DL: advisory boards for Roche, Amgen, MSD, GSK, Clovis, AstraZeneca, Immunogen, Genmab, Pharmamar and Merck, and grants for travelling from Pharmamar, GSK, Roche and AstraZeneca. CM: consulting/ advisory boards for Roche, Novartis, Amgen, MSD, AstraZeneca, Pfizer, Pharmamar, Cerulean, Vertex and Tesaro, funded research from EU, FWF, AstraZeneca and Roche, and honoraria/expenses from Roche, Novartis, Amgen, MSD, Pharmamar, AstraZeneca and Tesaro. JS: advisory boards for Roche, Eisei, MSD, AstraZeneca, Clovis, GSK and Tesaro. AT: advisory boards for Genmab; PW: advisory boards for Amgen, AstraZeneca, MSD, Novartis, Pfizer, Pharmamar, Lilly, Roche Pharma GmbH, TEVA, Eisai, Clovis and Tesaro, and grants for travelling from Roche Pharma GmbH, AstraZeneca, MSD, Amgen and Pfizer. NC: consulting and advisory services, speaking or writing engagements, public presentations for Roche, AstraZeneca, MSD, Pharmamar, Tesaro, GSK, Clovis, Advaxis, Pfizer, Takeda, Immunogen, Biocad, Amgen, Novartis and Ellipses, institutional financial interests for Roche, Pharmamar and AstraZeneca, and non-financial interests for ESMO clinical Guidelines (subject editor for gynecological cancer). XMG, SM, TB, SL, PM, RN, DOD, DQ, MRR, AS, AW, FP, and CLC: no conflicts of interest. Publisher Copyright: © 2021 IGCS and ESGO. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.
AB - A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.
KW - pathology
KW - radiation
KW - surgery
KW - uterine cancer
UR - http://www.scopus.com/inward/record.url?scp=85098118531&partnerID=8YFLogxK
U2 - https://doi.org/10.1136/ijgc-2020-002230
DO - https://doi.org/10.1136/ijgc-2020-002230
M3 - Review article
C2 - 33397713
SN - 1048-891X
VL - 31
SP - 12
EP - 39
JO - International journal of gynecological cancer
JF - International journal of gynecological cancer
IS - 1
ER -